GlaxoSmithKline and Pfizer's HIV Joint Venture Gets Priority Review for Dolutegravir

ViiV Healthcare, the HIV joint venture set up by GlaxoSmithKline (NYSE: GSK  ) and Pfizer (NYSE: PFE  ) , announced today that the Food and Drug Administration has granted its HIV drug, dolutegravir, a priority review.

Priority reviews are given to drugs that offer significant improvement over current treatments, or treat a disease where patients have no current options. The designation shortens the review time to eight months.

ViiV submitted the application on December 12, 2012, so it expects to hear back from the FDA by August 17. The company also submitted an application to market the drug in Europe and Canada on the same day.

Dolutegravir was tested in 2,553 patients with HIV/AIDS in four phase 3 clinical trials. The drug was developed by Japan-based Shionogi, which became a 10% equity owner in ViiV last October.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2259824, ~/Articles/ArticleHandler.aspx, 7/11/2014 12:34:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement